Stockreport

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]

IN8bio, Inc.  (INAB) 
PDF months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocol Median overall survival (mOS) continues to climb, [Read more]